Trump says envoy Witkoff had productive meeting with Putin
Smith & Nephew SNATS Inc stock reached a new 52-week high, climbing to 35.32 USD. This milestone reflects a positive shift in the company’s stock performance, with a notable 19.76% surge over the past six months. The $15.45 billion medical equipment manufacturer has shown resilience in a competitive market, maintaining dividend payments for 49 consecutive years with a current yield of 2.9%. This latest high marks a significant point in its trading history, with InvestingPro analysis suggesting the stock is trading near its Fair Value. Investors have responded positively to the company’s recent developments, contributing to the upward trend in its stock price. Get access to 8 more exclusive InvestingPro Tips and comprehensive analysis in the Pro Research Report.
In other recent news, Smith & Nephew announced it will release its second quarter and first half 2025 financial results on August 5, 2025. The company reported annual sales of $5.8 billion for 2024. Additionally, Smith & Nephew has appointed David King as an independent Non-Executive Director, effective July 1, 2025. King will also join the Compliance & Culture and Remuneration Committees. His extensive experience includes leadership roles at Fortis (NYSE:FTS) Life Sciences and Laboratory Corporation of America (NYSE:LH). These developments reflect the company’s ongoing efforts in financial transparency and leadership enhancement. Smith & Nephew is a constituent of the FTSE 100 index.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.